Research Experience 【 display / non-display 】

Research Experience 【 display / non-display 】

• 2022.04

  -

  Now

  Sapporo Medical University Hospital   Division of Laboratory Diagnosis   副部長

• 2021.02

  -

  Now

  Sapporo Medical University   血液内科学   講師

• 2007

  -

  2021.02

  Sapporo Medical University   School of Medicine   助教

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

• Life sciences   Hematology and oncology  

Affiliation 【 display / non-display 】

Affiliation 【 display / non-display 】

• Sapporo Medical University Hospital   Division of Laboratory Diagnosis   副部長  

Research Interests 【 display / non-display 】

Research Interests 【 display / non-display 】

• シグナル伝達

• 分子標的

• 活性酸素

• 内科

• CD34陽性細胞

display all >>

Papers 【 display / non-display 】

Papers 【 display / non-display 】

• Humanized <scp>anti‐IL</scp> ‐26 monoclonal antibody as a novel targeted therapy for chronic graft‐versus‐host disease

  Ryo Hatano, Takumi Itoh, Haruna Otsuka, Harumi Saeki, Ayako Yamamoto, Dan Song, Yuki Shirakawa, Satoshi Iyama, Tsutomu Sato, Noriaki Iwao, Norihiro Harada, Thomas M. Aune, Nam H. Dang, Yutaro Kaneko, Taketo Yamada, Chikao Morimoto, Kei Ohnuma

  American Journal of Transplantation ( Wiley )   2022.08

  DOI

• 血液疾患患者におけるCOVID-19感染症4例の報告(Four cases of COVID-19 patients with hematological malignancy)

  小野 賢人, 堀口 拓人, 下山 紗央莉, 藤田 千紗, 後藤 亜香利, 池田 博, 井山 諭, 村瀬 和幸, 高田 弘一, 藤谷 好弘, 高橋 聡, 黒沼 幸治, 小船 雅義

  日本血液学会学術集会 ( (一社)日本血液学会 )  83回   OS3 - 4  2021.09

• 未分化大細胞リンパ腫の加療中に発症したCOVID-19関連肺炎

  小野 賢人, 堀口 拓人, 下山 紗央莉, 藤田 千紗, 後藤 亜香利, 池田 博, 井山 諭, 藤谷 好弘, 高橋 聡, 黒沼 幸治, 小船 雅義

  臨床血液 ( (一社)日本血液学会-東京事務局 )  62 ( 7 ) 852 - 852  2021.07

• Six-transmembrane epithelial antigen of the prostate 1 accelerates cell proliferation by targeting c-Myc in liver cancer cells

  Kazutaka Iijima, Hajime Nakamura, Kohichi Takada, Naotaka Hayasaka, Tomohiro Kubo, Yui Umeyama, Satoshi Iyama, Koji Miyanishi, Masayoshi Kobune, Junji Kato

  Oncology Letters ( Spandidos Publications )  22 ( 1 )  2021.05

  DOI

• Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series.

  Osamu Honmou, Toshihiko Yamashita, Tomonori Morita, Tsutomu Oshigiri, Ryosuke Hirota, Satoshi Iyama, Junji Kato, Yuichi Sasaki, Sumio Ishiai, Yoichi M Ito, Ai Namioka, Takahiro Namioka, Masahito Nakazaki, Yuko Kataoka-Sasaki, Rie Onodera, Shinichi Oka, Masanori Sasaki, Stephen G Waxman, Jeffery D Kocsis

  Clinical neurology and neurosurgery   203   106565 - 106565  2021.04  [International journal]

  　View Summary

  BACKGROUND: Although spinal cord injury (SCI) is a major cause of disability, current therapeutic options remain limited. Recent progress in cellular therapy with mesenchymal stem cells (MSCs) has provided improved function in animal models of SCI. We investigated the safety and feasibility of intravenous infusion of MSCs for SCI patients and assessed functional status after MSC infusion. METHODS: In this phase 2 study of intravenous infusion of autologous MSCs cultured in auto-serum, a single infusion of MSCs under Good Manufacturing Practice (GMP) production was delivered in 13 SCI patients. In addition to assessing feasibility and safety, neurological function was assessed using the American Spinal Injury Association Impairment Scale (ASIA), International Standards for Neurological and Functional Classification of Spinal Cord (ISCSCI-92). Ability of daily living was assessed using Spinal Cord Independence Measure (SCIM-III). The study protocol was based on advice provided by the Pharmaceuticals and Medical Devices Agency in Japan. The trial was registered with the Japan Medical Association (JMA-IIA00154). RESULTS: No serious adverse events were associated with MSC injection. There was neurologic improvement based on ASIA grade in 12 of the 13 patients at six months post-MSC infusion. Five of six patients classified as ASIA A prior to MSC infusion improved to ASIA B (3/6) or ASIA C (2/6), two ASIA B patients improved to ASIA C (1/2) or ASIA D (1/2), five ASIA C patients improved and reached a functional status of ASIA D (5/5). Notably, improvement from ASIA C to ASIA D was observed one day following MSC infusion for all five patients. Assessment of both ISCSCI-92, SCIM-III also demonstrated functional improvements at six months after MSC infusion, compared to the scores prior to MSC infusion in all patients. CONCLUSION: While we emphasize that this study was unblinded, and does not exclude placebo effects or a contribution of endogenous recovery or observer bias, our observations provide evidence supporting the feasibility, safety and functional improvements of infused MSCs into patients with SCI.

  DOI PubMed

display all >>

Misc 【 display / non-display 】

Misc 【 display / non-display 】

• Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome

  Seitaro Terakura, Tetsuya Nishida, Masashi Sawa, Tomonori Kato, Kotaro Miyao, Yukiyasu Ozawa, Tatsunori Goto, Akio Kohno, Kazutaka Ozeki, Yasushi Onishi, Noriko Fukuhara, Nobuharu Fujii, Hisayuki Yokoyama, Masanobu Kasai, Hiroatsu Iida, Nobuhiro Kanemura, Tomoyuki Endo, Hiroatsu Ago, Makoto Onizuka, Satoshi Iyama, Yuichiro Nawa, Mika Nakamae, Yasuyuki Nagata, Shingo Kurahashi, Yasuo Tomiya, Atsumi Yanagisawa, Ritsuro Suzuki, Yachiyo Kuwatsuka, Yoshiko Atsuta, Koichi Miyamura, Makoto Murata

  Bone Marrow Transplantation ( Springer Science and Business Media LLC )  55 ( 7 ) 1399 - 1409  2020.07  [Refereed]  [International journal]

  　View Summary

  A prospectively registered observational study was conducted to assess the significance of allogeneic hematopoietic stem cell transplantation from highly HLA-matched unrelated donors (UD) and cord blood (CB) on outcomes in adult acute leukemia (AL) and myelodysplastic syndrome (MDS). Between 2007 and 2015, 231 transplant-eligible patients were registered for a phase 2 study of alternative donor transplantation. After registration, a sufficient time period was given to find appropriate UD. Patients received CB transplantation (CBT) if an appropriate UD was unavailable. In total, 119 patients received CBT (106 AL and 13 MDS) and 91 patients received UD transplantation (UDT) (86 AL and 5 MDS). The median age was 39 years in both groups. The primary objective was overall survival (OS); secondary objectives included cumulative incidences of non-relapse mortality (NRM) and relapse, and disease-free survival. Diagnosis, disease status at transplantation, refined disease risk index, and hematopoietic cell transplant-specific comorbidity index did not differ between UDT and CBT. In multivariate analyses, graft source was not a significant risk factor for all objectives. In adjusted analyses, UDT and CBT showed similar OS, NRM, and relapse in this prospective study. CB can be a comparable alternative stem cell source to UD by achieving a timely transplant.

  DOI PubMed

• Prospective Evaluation of Alternative Donor from Unrelated Volunteer Donor and Cord Blood in Adult Acute Leukemia and Myelodysplastic Syndrome: No Difference between Unrelated Donor and Cord Blood

  Seitaro Terakura, Tetsuya Nishida, Masashi Sawa, Tomonori Kato, Kotaro Miyao, Yukiyasu Ozawa, Tatsunori Goto, Akio Kohno, Kazutaka Ozeki, Yasushi Onishi, Noriko Fukuhara, Nobuharu Fujii, Hisayuki Yokoyama, Masanobu Kasai, Hiroatsu Iida, Nobuhiro Kanemura, Tomoyuki Endo, Hiroatsu Ago, Makoto Onizuka, Satoshi Iyama, Yuichiro Nawa, Mika Nakamae, Yasuyuki Nagata, Shingo Kurahashi, Yasuo Tomiya, Atsumi Yanagisawa, Ritsuro Suzuki, Yachiyo Kuwatsuka, Yoshiko Atsuta, Koichi Miyamura, Makoto Murata

  BLOOD ( AMER SOC HEMATOLOGY )  134  2019.11

  Research paper, summary (international conference)  

  　View Summary

  0

  DOI

• 【悪性黒色腫】 播種性骨髄癌腫症を呈した悪性黒色腫の1例

  澤田 匡秀, 澄川 靖之, 佐藤 さゆり, 菅 裕司, 加藤 潤史, 肥田 時征, 山下 利春, 橋本 亜香利, 井山 諭

  皮膚科の臨床 ( 金原出版(株) )  59 ( 13 ) 1963 - 1966  2017.12

  　View Summary

  79歳女。約2年前に左第4趾に黒色結節を自覚し、徐々に増大した。全切除生検を施行し、病理組織学的所見より悪性黒色腫と診断した。全身検索で他臓器転移を認めず、足趾離断術とセンチネルリンパ節生検を施行した。摘出した4個のリンパ節全てに転移を認めたため、鼠径、外腸骨、閉鎖リンパ節郭清を追加した。郭清したリンパ節に転移はなかった。pT3bN3M0 Stage IIICと診断し、術後化学療法としてDAV-Feron療法を計6クール施行した。以後はフェロン局注療法を継続していたが、術後約3年3ヵ月で突然強い腰痛が出現した。各種画像所見、臨床検査所見、骨髄生検の病理組織所見より、悪性黒色腫による播種性骨髄癌腫症とした。化学療法を施行するも改善なく、入院から19日後に永眠された。

  DOI

• P53-RESTORING SMALL MOLECULE CP-31398 INDUCES APOPTOSIS VIA INDUCTION OF REACTIVE OXIDATIVE SPECIES IN HUMAN MULTIPLE MYELOMA

  Y. Arihara, K. Takada, Y. Kawano, N. Hayasaka, H. Nakamura, S. Kikuchi, Y. Kamihara, K. Murase, H. Ikeda, S. Iyama, T. Sato, K. Miyanishi, M. Kobune, J. Kato

  HAEMATOLOGICA ( FERRATA STORTI FOUNDATION )  102   498 - 498  2017.06

  Research paper, summary (international conference)  

• Next Generation Sequencing of CD138+Myeloma Cells Could Predict Response Rate and Appropriate Therapy at Diagnosis

  Hiroshi Ikeda, Yasushi Sasaki, Soushi Ibata, Masahiro Yoshida, Ayumi Tatekoshi, Satoshi Iyama, Kazuyuki Murase, Kohichi Takada, Shohei Kikuchi, Tsutomu Sato, Masayoshi Kobune, Junji Kato

  BLOOD ( AMER SOC HEMATOLOGY )  128 ( 22 )  2016.12

  Research paper, summary (international conference)  

display all >>

Awards 【 display / non-display 】

Awards 【 display / non-display 】

• 小越章平記念 Best Paer in The Year 2021

  2022.05   Japanese Society for Clinical Nutrition and Metabolism   Possible clinical outcomes using early enteral nutrition in individuals with allogeneic hematopoietic stem cell transplantation: A single-center retrospective study.

  Winner： 井山 諭

Research Projects 【 display / non-display 】

Research Projects 【 display / non-display 】

• Development of new therapy for AML by targeting of neuropeptide-PTH2R system

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2022.04

  -

  2025.03

   

  小船 雅義, 井山 諭, 池田 博, 後藤 亜香利, 堀口 拓人

• Analysis of the development and pathogenesis of AML/MDS via extracellular vesicles

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2019.04

  -

  2022.03

   

  Kobune Masayoshi

  Authorship： Coinvestigator(s)

  　View Summary

  The analysis of exome in MDS and AML has revealed the multiple mutations involved in the pathogenesis of these disorders. On the other hand, it has been increasingly focused on the dysfunction of BM microenvironment in the MDS/AML. However, little is known how the dysfunction of BM microenvironment was induced. In this study, high level of miR-7977, miR-8073, and miR-4286 were identified in extracellular vesicles from AML cells. In particular, miR-7977 effect on BM MSCs to reduce the expression of PCBP1 and STK4, resulting in the reduction of multiple mRNA and Hippo signaling, suggesting that it could be involved in the alteration of BM microenvironment favorable to leukemia cell survival. In addition, the possibility of rejuvenation by extracellular vesicles derived from immature cells was investigated. Although the expression of β galactosidase was slightly decreased, no changes of other aging markers were detected. Other strategy may be required for rejuvenation of aging MSCs.

• Efficacy for treating MM with DPP8/9 inhibitor.

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2015.04

  -

  2018.03

   

  Iyama Satoshi

  Authorship： Principal investigator

  　View Summary

  Recently, the prognosis of patients with multiple myeloma (MM) has considerably improved due to the use of autologous hematopoietic stem cell transplantation and the introduction of new agents such as the immunomodulatory drugs, proteasome inhibitors. However, no curable treatment is available. We have previously shown that the DPP8/9 inhibitor, 1G244, induced MM cells to cell death by apoptosis. Hence, we demonstrated efficacy for treating MM with DPP8/9 inhibitor.

• Novel strategy against GVHD using NB-UVB with expansion of Treg cells

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2013.04

  -

  2016.03

   

  Sato Tsutomu, Iyama Satoshi, Kawano Yutaka

  Authorship： Coinvestigator(s)

  　View Summary

  Narrowband ultraviolet B (NB-UVB) has been widely used in dermatological phototherapy. As for the application of NB-UVB phototherapy to GVHD, we previously reported that it was highly efficacious for cutaneous lesions of acute GVHD (aGVHD) and that expansion of regulatory T (Treg) cells induced by NB-UVB might be one of the mechanisms. In order to examine whether NB-UVB irradiation through expansion of Treg cells is effective for the treatment of not only cutaneous aGVHD but also aGVHD of inner organs such as the intestine or liver, we conducted experiments in which a murine lethal aGVHD model, characterized by severe involvement of the intestine, were irradiated with NB-UVB. We found that NB-UVB irradiation improved the clinical score and survival rate. The numbers of infiltrating Treg cells in inflamed tissue of the intestine and those in spleen were increased in mice treated with NB-UVB.

• Establishment of iron chelation therapy to inhibit the development of MDS

  Grant-in-Aid for Challenging Exploratory Research

  Project Year :

  2012.04

  -

  2015.03

   

  KOBUNE Masayoshi, KIKUCHI Shohei, IYAMA Satoshi, KATO Junji

  Authorship： Coinvestigator(s)

  　View Summary

  Most MDS patients eventually require red RBC transfusions for anemia and consequently develop iron overload. Excess free iron in cells catalyzes generation of reactive oxygen species that cause oxidative stress, including oxidative DNA damage. However, it is uncertain how iron-mediated oxidative stress affects the pathophysiology of MDS. We analyzed 8-OHdG levels in peripheral blood mononuclear cells (PBMC) obtained from MDS patients before and after iron chelator,deferasirox, administration. We showed that the 8-OHdG levels in MDS patients were significantly higher than those in healthy volunteers and were positively correlated with SF and chromosomal abnormalities. Importantly, the 8-OHdG levels in PBMC of MDS patients significantly decreased after deferasirox administration, suggesting that iron chelation reduced oxidative DNA damage. Thus, excess iron could contribute to the pathophysiology of MDS and iron chelation therapy could improve the oxidative DNA damage in MDS patients.

display all >>